TD Cowen initiates Teva Pharma stock with buy rating on pipeline

TD Cowen has started covering Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) with a positive outlook, assigning it a "buy" rating and setting an anticipated price of $55.00 per share. This projection suggests a potential increase of around 39% from the current market price of $39.60, which is close to the stock's recent 52-week high of $40.79.

Over the last year, Teva shares have seen a significant 98% growth. The brokerage firm highlights Teva as a large-scale biopharmaceutical company, specializing in generic and biosimilar products alongside a rapidly expanding range of therapeutics. Within the neuropsychiatry and central nervous system (CNS) categories, Teva's established medications are expected to continue their upward trajectory.

Potential upcoming product launches, such as ecopipam and olanzapine LAI, are anticipated to further fuel the company's growth. TD Cowen's valuation of the stock, based on a net present value analysis, is led by analyst Joseph Thome. The firm's assessment is supported by a range of compelling factors, notably their pipeline advancements, including duvakitug, TEV-408, and DARI, which are seen as key drivers for their optimistic outlook.

However, it's worth noting that TEVA is currently marked as overvalued according to the platform's analysis. Investors looking for more in-depth information about Teva can access comprehensive Pro Research Reports, which provide a detailed, easy-to-understand breakdown of the company's financials and market position. Recently, Teva has made several notable advancements.

The U.S. Food and Drug Administration has approved Teva's New Drug Application for ecopipam, a medication aimed at treating pediatric Tourette syndrome, with a projected approval date in the first quarter of 2027. Additionally, Moody's Ratings has upgraded Teva to an investment grade, recognizing the company's thriving business strategy, expanding branded drug sales, and successful debt reduction.

This upgrade reflects Teva's enhanced leverage metrics and overall financial health. Other industry bodies, including Oppenheimer and UBS, have also shown confidence in Teva, with Oppenheimer rating the stock as "outperform" and UBS raising its price target, both highlighting the company's strong sales growth potential from key products.

Furthermore, Teva has reached a patent settlement with Aurinia Pharmaceuticals, paving the way for the future production of a generic version of voclosporin. These recent developments underscore Teva's continued focus on enhancing its product portfolio and financial performance.